🔗 Visit the ClinicalTrials.gov page for NCT02821754
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. | N Engl J Med | 2012 | 35.24 |
| 2 | A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. | J Hepatol | 2013 | 2.63 |
| 3 | Immunological off-target effects of standard treatments in gastrointestinal cancers. | Ann Oncol | 2013 | 0.81 |
| 4 | Application of the Immunoscore as prognostic tool for hepatocellular carcinoma. | J Immunother Cancer | 2016 | 0.75 |